CNS Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for CNS Pharmaceuticals.

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

According to 1 stock analyst, the rating for CNS Pharmaceuticals is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	1	1	1	1	0
Buy	0	0	0	0	0
Hold	0	0	0	0	1
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason McCarthy Maxim Group	Maxim Group	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Mar 25, 2025
Jason McCarthy Maxim Group	Maxim Group	Hold → Strong Buy Upgrades $25	Hold → Strong Buy	Upgrades	$25	+1,878.16%	Sep 10, 2024
Raja Kumaraguru Brookline Capital	Brookline Capital	Strong Buy Initiates $750,000	Strong Buy	Initiates	$750,000	+59,344,733.04%	Feb 2, 2021
Robert LeBoyer Ladenburg Thalmann	Ladenburg Thalmann	Strong Buy Initiates $825,000	Strong Buy	Initiates	$825,000	+65,279,216.35%	Aug 24, 2020

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

n/a

EPS Next Year

n/a

Fiscal Year	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-
Revenue Growth	-	-	-	-	-	-	-	-
EPS	-0.87	-0.40	-0.37
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-
No. Analysts	-	-	-	-	-	3	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2024	2025	2026
High	n/a	n/a	n/a
Avg	n/a	n/a	n/a
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2024	2025	2026
High	-	-	-
Avg	-	-	-
Low	-	-	-

EPS Forecast

EPS	2024	2025	2026
High	-0.89	-0.41	-0.38
Avg	-0.87	-0.40	-0.37
Low	-0.83	-0.38	-0.35

EPS Growth

EPS Growth	2024	2025	2026
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.